About Us

Between 1990 and 2012, Dr. Glazier’s research focused on understanding the logical requirements for curing cancer without significant side effects. This involved identifying possible methods of overcoming drug resistance caused by tumor cell evolution.

In 2012, Dr. Glazier’s sister, Sharon Seibel, M.D., who has an inherited BRCA2 mutation, was diagnosed with pancreatic cancer. She received radiation therapy followed by surgical resection. Her cancer had spread to 7 of the 13 resected lymph nodes, including a common hepatic artery lymph node (CHALN). Published literature associates surgically resected cancer in the presence of a positive CHALN with a zero percent chance of survival. For that reason, as well as the high rate of neurotoxicity caused by standard of care, Dr. Seibel declined traditional chemotherapy.

Dr. Glazier pivoted from researching the requirements for developing a cure without significant patient toxicity to the urgent problem of designing a cure for his sister with only reversible toxicity. Given the need for an immediately available solution, the treatment could only use previously FDA-approved drugs.

Dr. Seibel ultimately received a treatment proposed by Dr. Glazier. That treatment led to the development of General Oncology’s clinical-phase drug candidate, GO-4.

Dr. Seibel remains alive and well today. She received no chemotherapy other than the precursor treatment to GO-4. She has not received any maintenance drugs. She has remained pancreatic cancer-free since 2012, now more than 13 years, with no lasting side effects from the treatment.

In 2021, General Oncology sponsored the SHARON trial to study GO-4 in pancreatic and breast cancer patients with an inherited BRCA mutation. The study is nearly complete, and preliminary results were presented at ESMO in October 2025. A phase 1 expansion began in January 2026 and will be followed by a potentially pivotal phase 2 study.